In a decisive action aimed at addressing the growing mental health crisis, President Donald Trump signed an executive order directing the Food and Drug Administration (FDA) to accelerate the review process for psychedelics categorized as breakthrough therapy drugs. This executive mandate is positioned by the administration as a necessary